Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

Bibliographic Details
Main Authors: Lip, Gregory Y. H., Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Bruno, Amanda, Phatak, Hemant
Format: Online
Language:English
Published: John Wiley and Sons Inc. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129572/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129572/

Similar Items